Form 4: Erasca Inc. Executive Ebun Garner Reports Stock Option Grant

Ebun Garner, General Counsel & Corp. Sec. of Erasca, Inc., reports the acquisition of stock options.

Summary

• On June 20, 2024, Ebun Garner, General Counsel & Corp. Sec. of Erasca, Inc., acquired stock options for 160,082 shares.
• The exercise price of the options is $2.03.
• The options vest monthly, with 1/48th of the shares vesting each month starting on June 20, 2024, contingent upon continuous service to Erasca.
• The expiration date for the options is June 19, 2034.
• Following the transaction, Garner directly owns 160,082 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally viewed neutrally to positively as it aligns management incentives with shareholder value.

Positives

• The grant of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
• The vesting schedule of 1/48th monthly is a fairly standard vesting schedule.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of the shareholders, incentivizing them to increase the company's stock value.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates